Long after the blockbuster shoutouts faded to a whisper, TherapeuticsMD gets an M&A deal
Long after TherapeuticsMD’s boasts of blockbuster aspirations in the women’s health field had melted away to a revenue stream counted in droplets, the micro biotech player is being snapped up by a private equity group in an M&A deal valued at $177 million.
The biotech put out word early Tuesday that EW Healthcare Partners agreed to pay $10 a share for all outstanding shares $TXMD of the company, more than tripling the value of the badly battered stock in an instant. Over the past 5 years, the one-time high flyer has seen its stock price dwindle by more than 99% as boasts gave way to a grim reality.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.